Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia

Published:2024-09-05 Issue:10 Volume:144 Page:1127-1130
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Walczak Pierre¹,Fodil Sofiane¹²^ORCID,Vignal Nicolas³^ORCID,Cabannes-Hamy Aurélie⁴,Boissel Nicolas¹²^ORCID,Raffoux Emmanuel¹²,Cayuela Jean-Michel⁵,Goldwirt Lauriane³^ORCID,Lengliné Etienne¹^ORCID

Affiliation:

1. 1Hematology Department, Saint-Louis Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

2. 2Université de Paris Cité, Paris, France

3. 3Pharmacology Department, Saint-Louis Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

4. 4Hematology Department, Centre Hospitalier de Versailles, Versailles, France

5. 5Laboratory of Hematology, University Hospital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris, France

Abstract

Abstract Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell below the 40 nM threshold, suggesting suboptimal CNS exposure.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/144/10/1127/2240683/blood_bld-2024-024838-main.pdf

Reference25 articles.

1. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia;Kopmar;Blood,2022

2. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation;Tang;Blood,2021

3. Central nervous system relapse in adults with acute lymphoblastic leukemia;Surapaneni;Cancer,2002

4. Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group;Pinnix;Int J Radiat Oncol Biol Phys,2018

5. Management of ALL in adults: 2023 ELN recommendations from a European expert panel;Gökbuget;Blood,2024